Integrative Physiology |
and -ß Blockade on Flow-Induced Neointimal Formation in Endothelialized Baboon Vascular Grafts
From the Division of Vascular Surgery (M.G.D., E.L.O., D.P.M., H.L., P.K.T., S.V., S.A.H., A.W.C.), Department of Surgery, University of Washington, Seattle, Wash, and ZymoGenetics Inc (C.E.H.), Seattle, Wash.
Correspondence to Alexander W. Clowes, MD, Division of Vascular Surgery, Department of Surgery, University of Washington School of Medicine, HSB BB442; Box 356410, 1959 NE Pacific St, Seattle, WA 98195-6410. E-mail clowes{at}u.washington.edu
AbstractThe growth of
neointima and neointimal smooth muscle cells in
baboon polytetrafluoroethylene grafts is
regulated by blood flow. Because neointimal smooth muscle
cells express both platelet-derived growth factor receptor-
and
-ß (PDGFR-
and -ß), we designed this study to test the
hypothesis that inhibiting either PDGFR-
or PDGFR-ß with a
specific mouse/human chimeric antibody will modulate flow-induced
neointimal formation. Bilateral aortoiliac grafts and
distal femoral arteriovenous fistulae were placed in 17 baboons. After
8 weeks, 1 arteriovenous fistulae was ligated, normalizing flow through
the ipsilateral graft while maintaining high flow in the contralateral
graft. The experimental groups received a blocking antibody to
PDGFR-
(Ab-PDGFR-
; 10 mg/kg; n=5) or PDGFR-ß (Ab-PDGFR-ß; 10
mg/kg; n=6) by pulsed intravenous administration 30 minutes
before ligation and at 4, 8, 15, and 22 days after ligation. Controls
received carrier medium alone (n=8). Serum antibody concentrations were
followed. Grafts were harvested after 28 days and analyzed by
videomorphometry. Serum Ab-PDGFR-
concentrations fell rapidly after
day 7 to 0, whereas serum Ab-PDGFR-ß concentrations were maintained
at the target levels (>50 µg/mL). Compared with controls (3.7±0.3),
the ratio of the intimal areas (normalized flow/high flow) was
significantly reduced in Ab-PDGFR-ß (1.2±0.2,
P<0.01) but not in Ab-PDGFR-
(2.2±0.4).
Ab-PDGFR-
decreased significantly the overall smooth muscle cell
nuclear density of the neointima (P<0.01)
compared with either the control or Ab-PDGFR-ß treated groups.
PDGFR-ß is necessary for flow-induced neointimal
formation in prosthetic grafts. Targeting PDGFR-ß may be an
effective pharmacological strategy for suppressing graft
neointimal development.
Key Words: neointimal hyperplasia platelet-derived growth factor receptors smooth muscle cells shear stress
This article has been cited by other articles:
![]() |
R. Castelli, L. Bergamaschini, P. Sailis, G. Pantaleo, and F. Porro The Impact of an Aging Population on the Diagnosis of Pulmonary Embolism: Comparison of Young and Elderly Patients Clinical and Applied Thrombosis/Hemostasis, February 1, 2009; 15(1): 65 - 72. [Abstract] [PDF] |
||||
![]() |
J. A. Thomas, R. A. Deaton, N. E. Hastings, Y. Shang, C. W. Moehle, U. Eriksson, S. Topouzis, B. R. Wamhoff, B. R. Blackman, and G. K. Owens PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H442 - H452. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Bonello, Y. V. Bobryshev, and L. M. Khachigian Peroxide-Inducible Ets-1 Mediates Platelet-Derived Growth Factor Receptor-{alpha} Gene Transcription in Vascular Smooth Muscle Cells Am. J. Pathol., October 1, 2005; 167(4): 1149 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.C. Jayson, G.J.M. Parker, S. Mullamitha, J.W. Valle, M. Saunders, L. Broughton, J. Lawrance, B. Carrington, C. Roberts, B. Issa, et al. Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume J. Clin. Oncol., February 10, 2005; 23(5): 973 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Kenagy, J. W. Fischer, S. Lara, J. D. Sandy, A. W. Clowes, and T. N. Wight Accumulation and Loss of Extracellular Matrix During Shear Stress-mediated Intimal Growth and Regression in Baboon Vascular Grafts J. Histochem. Cytochem., January 1, 2005; 53(1): 131 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Owens, M. S. Kumar, and B. R. Wamhoff Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease Physiol Rev, July 1, 2004; 84(3): 767 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Leppanen, J. Rutanen, M. O. Hiltunen, T. T. Rissanen, M. P. Turunen, T. Sjoblom, J. Bruggen, G. Backstrom, M. Carlsson, E. Buchdunger, et al. Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits Circulation, March 9, 2004; 109(9): 1140 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Paszkowiak and A. Dardik Arterial Wall Shear Stress: Observations from the Bench to the Bedside Vascular and Endovascular Surgery, January 1, 2003; 37(1): 47 - 57. [Abstract] [PDF] |
||||
![]() |
K. Kozaki, W. E. Kaminski, J. Tang, S. Hollenbach, P. Lindahl, C. Sullivan, J.-C. Yu, K. Abe, P. J. Martin, R. Ross, et al. Blockade of Platelet-Derived Growth Factor or Its Receptors Transiently Delays but Does Not Prevent Fibrous Cap Formation in ApoE Null Mice Am. J. Pathol., October 1, 2002; 161(4): 1395 - 1407. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Nathe, J. Deou, B. Walsh, B. Bourns, A. W. Clowes, and G. Daum Interleukin-1{beta} Inhibits Expression of p21(WAF1/CIP1) and p27(KIP1) and Enhances Proliferation in Response to Platelet-Derived Growth Factor-BB in Smooth Muscle Cells Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1293 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Horvath, F. G.P. Welt, M. Nedelman, P. Rao, and C. Rogers Targeting CCR2 or CD18 Inhibits Experimental In-Stent Restenosis in Primates: Inhibitory Potential Depends on Type of Injury and Leukocytes Targeted Circ. Res., March 8, 2002; 90(4): 488 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamasaki, K. Miyoshi, N. Oda, M. Watanabe, H. Miyake, J. Chan, X. Wang, L. Sun, C. Tang, G. McMahon, et al. Weekly Dosing With the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor SU9518 Significantly Inhibits Arterial Stenosis Circ. Res., March 30, 2001; 88(6): 630 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Leppanen, N. Janjic, M.-A. Carlsson, K. Pietras, M. Levin, C. Vargeese, L. S. Green, D. Bergqvist, A. Ostman, and C.-H. Heldin Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model Arterioscler Thromb Vasc Biol, November 1, 2000; 20 (11): e89 - e95. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Horvath, F. G.P. Welt, M. Nedelman, P. Rao, and C. Rogers Targeting CCR2 or CD18 Inhibits Experimental In-Stent Restenosis in Primates: Inhibitory Potential Depends on Type of Injury and Leukocytes Targeted Circ. Res., March 8, 2002; 90(4): 488 - 494. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |